Literature DB >> 12595974

The cost effectiveness of lung transplantation compared with that of heart and liver transplantation in the Netherlands.

Jan Paul Ouwens1, Petra J van Enckevort, Els M TenVergert, Gauke J Bonsel, Wim van der Bij, Els B Haagsma, Frans F H Rutten, Maarten J H Slooff, Gerard H Koëter.   

Abstract

This study was performed to assess the main reasons for the unfavorable cost effectiveness of lung transplantation compared with that of heart and liver transplantation. Costs, effects, and cost-effectiveness ratios of Dutch lung, heart, and liver transplantation programs were compared. The data are based on three Dutch technology assessments of transplantation, with minor adjustments for time and methods. In result, mainly follow-up costs of lung transplantation are higher than costs of heart and liver transplantation-- 50,300 US dollars, 121,500 US dollars, and 95,300 US dollars, respectively--in the first 3 years after transplantation. The survival gain realized by lung transplantation is small (4.4 years) compared with heart (8.8 years) and liver (14.7 years) transplantation. Costs per life-year gained were 77,000 US dollars, 38,000 US dollars, and 26,000 US dollars for lung, heart, and liver transplantation, respectively. The unfavorable cost effectiveness of lung transplantation is largely related to a relatively small survival gain and high follow-up costs.

Mesh:

Year:  2003        PMID: 12595974     DOI: 10.1007/s00147-002-0508-8

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  4 in total

Review 1.  Developments in liver transplantation.

Authors:  J Neuberger
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

Review 2.  Cost-effectiveness analysis of TAVR.

Authors:  Michael J Reardon
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Apr-Jun

3.  Cost-effectiveness of heart failure therapies.

Authors:  Luis E Rohde; Eduardo G Bertoldi; Livia Goldraich; Carísi A Polanczyk
Journal:  Nat Rev Cardiol       Date:  2013-04-23       Impact factor: 32.419

Review 4.  Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.

Authors:  Jörn M Schattenberg; Jeffrey V Lazarus; Philip N Newsome; Lawrence Serfaty; Alessio Aghemo; Salvador Augustin; Emmanuel Tsochatzis; Victor de Ledinghen; Elisabetta Bugianesi; Manuel Romero-Gomez; Heike Bantel; Stephen D Ryder; Jerome Boursier; Vincent Leroy; Javier Crespo; Laurent Castera; Lefteris Floros; Vincenzo Atella; Jorge Mestre-Ferrandiz; Rachel Elliott; Achim Kautz; Alice Morgan; Sally Hartmanis; Sharad Vasudevan; Lynne Pezzullo; Aldo Trylesinski; Sandrine Cure; Victoria Higgins; Vlad Ratziu
Journal:  Liver Int       Date:  2021-03-18       Impact factor: 5.828

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.